Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
Karyopharm hopes to move Xpovio earlier in the multiple myeloma treatment sequence, and data are due for Akcea/Ionis’s triglyceride regulator, for which Pfizer paid a…
Available to download for free now, our annual preview takes a data-driven look at 2020. Uncover biopharma’s biggest growth drivers, and see where the money is flowing.
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
Two phase III studies could determine whether the Canadian biotech has an approvable product, but the setting will initially be narrow.
Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.
Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.